Rafael (NYSE:RFL) Announces Quarterly Earnings Results

Rafael (NYSE:RFL) announced its quarterly earnings data on Monday. The company reported ($0.13) earnings per share for the quarter, FiscalAI reports. Rafael had a negative return on equity of 32.82% and a negative net margin of 3,044.70%.The business had revenue of $0.21 million during the quarter.

Rafael Stock Up 5.9%

NYSE:RFL opened at $1.36 on Tuesday. Rafael has a 52 week low of $1.12 and a 52 week high of $3.19. The firm has a 50 day moving average of $1.28 and a 200 day moving average of $1.31. The stock has a market capitalization of $70.15 million, a price-to-earnings ratio of -1.59 and a beta of 0.58.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Rafael in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Rafael currently has an average rating of “Sell”.

Institutional Investors Weigh In On Rafael

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RFL. Simplex Trading LLC acquired a new position in Rafael during the second quarter worth $32,000. Marshall Wace LLP acquired a new position in Rafael during the second quarter worth $50,000. Citadel Advisors LLC lifted its stake in Rafael by 132.3% during the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after acquiring an additional 41,335 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Rafael by 25.4% during the 4th quarter. Geode Capital Management LLC now owns 445,866 shares of the company’s stock valued at $526,000 after acquiring an additional 90,417 shares during the period. Finally, Cable Car Capital LP acquired a new position in Rafael in the 2nd quarter valued at about $173,000. 11.30% of the stock is currently owned by hedge funds and other institutional investors.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.